End-to-End Platform for Human Pluripotent Stem Cell Manufacturing
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Industrialization of stem-cell based therapies requires innovative solutions to close the gap between research and commercialization. Scalable cell production platforms are needed to reliably deliver the cell quantities needed during the various stages of development and commercial supply. Human pluripotent stem cells (hPSCs) are a key source material for generating therapeutic cell types. We have developed a closed, automated and scalable stirred tank bioreactor platform, capable of sustaining high fold expansion of hPSCs. Such a platform could facilitate the in-process monitoring and integration of online monitoring systems, leading to significantly reduced labor requirements and contamination risk. hPSCs are expanded in a controlled bioreactor using perfused xeno-free media. Cell harvest and concentration are performed in closed steps. The hPSCs can be cryopreserved to generate a bank of cells, or further processed as needed. Cryopreserved cells can be thawed into a two-dimensional (2D) tissue culture platform or a three-dimensional (3D) bioreactor to initiate a new expansion phase, or be differentiated to the clinically relevant cell type. The expanded hPSCs express hPSC-specific markers, have a normal karyotype and the ability to differentiate to the cells of the three germ layers. This end-to-end platform allows a large scale expansion of high quality hPSCs that can support the required cell demand for various clinical indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures












Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While culturing iPSCs as aggregates involves 2D to 3D adaptation and frequent cell passaging to control the size of the cell aggregates, the cells could be directly used for downstream processes such as cryopreservation and differentiation [79,81].”
From Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies (2023) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In this process, iPSCs were cultured in agitation, on microcarriers, with no passaging for 12–14 days, followed by steps of dissociation from the”
From Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies (2023) · cites this paper as [81]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“An end-to-end process of thawing and expanding iPSCs in a stirred tank bioreactor was recently described [81].”
From Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Culturing iPSCs in a stirred tank bioreactor on microcarriers could be an attractive way to achieve large cell quantities in a relatively short time, without the need for 2D to 3D adaptation or passaging [81].”
From Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies (2023) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310 · cited 1×
“Successful generation of human-induced pluripotent stem cells (hiPSCs) by somatic cell reprogramming has opened new avenues in regenerative medicine, disease modeling and drug development [1,2].”
BackgroundLian, X., Zhang, J., Azarin, S. M., Zhu, K., Hazeltine, L. B., Bao, X., Hsiao, C., Kamp, T. J., & Palecek, S. P. (2013) · Nature Protocols · doi:10.1038/nprot.2012.150 · Cited by 1,748 · cited 2×
“Human iPSCs were differentiated into cardiomyocytes using the Gsk3 inhibitor and Wnt inhibitor (GiWi) protocol as previously described [5,40,41].”
BackgroundMethodLian, X., Hsiao, C., Wilson, G., Zhu, K., Hazeltine, L. B., Azarin, S. M., Raval, K. K., Zhang, J., Kamp, T. J., & Palecek, S. P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200250109 · Cited by 1,717 · cited 1×
“Human iPSCs were differentiated into cardiomyocytes using the Gsk3 inhibitor and Wnt inhibitor (GiWi) protocol as previously described [5,40,41].”
Functional Cardiomyocytes Derived From Human Induced Pluripotent Stem Cells
Zhang, J., Wilson, G. F., Soerens, A. G., Koonce, C. H., Yu, J., Palecek, S. P., Thomson, J. A., & Kamp, T. J. (2009) · Circulation Research · doi:10.1161/circresaha.108.192237 · Cited by 1,407 · cited 1×
“Human iPSCs were differentiated into cardiomyocytes using the Gsk3 inhibitor and Wnt inhibitor (GiWi) protocol as previously described [5,40,41].”
MethodThe promise of induced pluripotent stem cells in research and therapy
Robinton, D. A., & Daley, G. Q. (2012) · Nature · doi:10.1038/nature10761 · Cited by 1,111 · cited 1×
“Capable of self-renewal and pluripotency, hiPSCs derived from patients of both normal and aberrant phenotypes provide a theoretically limitless supply of clinically relevant iPSC-derived cells without ethical limitations and immune-rejection [3,4].”
BackgroundEngineering Adolescence: Maturation of Human Pluripotent Stem Cell–Derived Cardiomyocytes
Yang, X., Pabon, L., & Murry, C. E. (2014) · Circulation Research · doi:10.1161/circresaha.114.300558 · Cited by 939 · cited 1×
“Moreover, iPSC-derived cardiomyocytes remain phenotypically immature [8], despite a number of studies demonstrating enhanced maturation through the modulation of existing methodologies [9–13].”
BackgroundOkita, K., Yamakawa, T., Matsumura, Y., Sato, Y., Amano, N., Watanabe, A., Goshima, N., & Yamanaka, S. (2013) · Stem Cells · doi:10.1002/stem.1293 · Cited by 749 · cited 1×
“To reprogram the cells, 1× 106 PBMNCs were nucleofected with the episomal plasmids pCE-hOCT3/4, pCE-hSK, pCE-hUL, pCE-mP53DD and pCXB-EBNA-1 [37].”
MethodMummery, C. L., Zhang, J., Ng, E. S., Elliott, D. A., Elefanty, A. G., & Kamp, T. J. (2012) · Circulation Research · doi:10.1161/circresaha.110.227512 · Cited by 713 · cited 2×
“To replace the number of cells lost during a myocardial infarction, for example, approximately 1 × 109 cells are required per patient dose [7].”
BackgroundYang, X., Rodriguez, M., Pabon, L., Fischer, K. A., Reinecke, H., Regnier, M., Sniadecki, N. J., Ruohola-Baker, H., & Murry, C. E. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.04.005 · Cited by 431
Research works printed but not linked: 1
- Batalov, 2015, Differentiation of cardiomyocytes from human pluripotent stem cells using monolayer culture, Biomark. Insights, 10, 71
Cited by
Chen, H., Deng, J., Yao, X., He, Y., Li, H., Jian, Z., Tang, Y., Zhang, X., Zhang, J., & Dai, H. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01088-9 · Cited by 74
Advances in automated cell washing and concentration
Li, A., Kusuma, G. D., Driscoll, D., Smith, N., Wall, D. M., Levine, B. L., James, D., & Lim, R. (2021) · Cytotherapy · doi:10.1016/j.jcyt.2021.04.003 · Cited by 49
Rivera-Ordaz, A., Peli, V., Manzini, P., Barilani, M., & Lazzari, L. (2021) · BioDrugs · doi:10.1007/s40259-021-00503-9 · Cited by 46
Schwertfirm, G., Schneider, M. C., Haase, F., Riedel, C., Lazzaro, M., Ruge‐Wehling, B., & Schweizer, G. (2024) · Theoretical and Applied Genetics · doi:10.1007/s00122-024-04665-2 · Cited by 44
Boussaad, I., Cruciani, G., Bolognin, S., Antony, P., Dording, C. M., Kwon, Y.-J., Heutink, P., Fava, E., Schwamborn, J. C., & Krüger, R. (2021) · Scientific Reports · doi:10.1038/s41598-021-81129-3 · Cited by 42
“(1) Liquid handler Biomek NX Span-8 including the plate shaker Shaking Peltier ALP and a tilting station Amplius (AIG) 3D Tilting ALP, (2) Liquid handler Biomek FXP (96- and 384-pipetting head including active wash-station and a BioShake 3000, (3) Acoustic droplet ejector Labcyte Echo550, (4) High content imager Yokog…”
Method
Metadata
- Authors
- Pandey, P. R., Tomney, A., Woon, M. T., Uth, N., Shafighi, F., Ngabo, I., Vallabhaneni, H., Levinson, Y., Abraham, E., & Friedrich Ben-Nun, I.
- Affiliations
- Lonza (United States) (US)
- Cell and Gene Therapy Research and Development, Lonza Inc., Rockville, MD 20850, USA
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-12-21
- Volume
- 21
- Issue
- 1
- Pages
- 89
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6981419
- OpenAlex
- W2995477520
- Cited by
- 42
- References
- 46
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 6 · 2023: 6 · 2022: 9 · 2021: 8 · 2020: 2 · 2019: 1
- FWCI
- 1.66
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Keywords
- human pluripotent stem cells, stem cell manufacturing, stirred tank bioreactor, cell cryopreservation, cell banking, stem cell differentiation, three germ layers, contamination risk reduction
- MeSH terms
- Cellular Reprogramming Techniques, Cell Differentiation, Cells, Cultured, Humans, Bioreactors, Myocytes, Cardiac, Cell Proliferation, Induced Pluripotent Stem Cells, Automation, Laboratory, Primary Cell Culture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: End-to-End Platform for Human Pluripotent Stem Cell Manufacturing. https://app.cochat.ai/papers/10.3390/ijms21010089
- The paper
- Pandey, P. R., Tomney, A., Woon, M. T., Uth, N., Shafighi, F., Ngabo, I., Vallabhaneni, H., Levinson, Y., Abraham, E., & Friedrich Ben-Nun, I. (2019). End-to-End Platform for Human Pluripotent Stem Cell Manufacturing. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21010089
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.